|
1
|
Huang L, Zhang T, Xie C, Liao X, Yu Q,
Feng J, Ma H, Dai J, Li M, Chen J, et al: SLCO1B1 and SLC19A1 gene
variants and irinotecan-induced rapid response and survival: A
prospective multicenter pharmacogenetics study of metastatic
colorectal cancer. PLoS One. 8:e772232013. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
De Mattia E, Toffoli G, Polesel J,
D'Andrea M, Corona G, Zagonel V, Buonadonna A, Dreussi E and
Cecchin E: Pharmacogenetics of ABC and SLC transporters in
metastatic colorectal cancer patients receiving first-line FOLFIRI
treatment. Pharmacogenet Genomics. 23:549–557. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Ramsey LB, Panetta JC, Smith C, Yang W,
Fan Y, Winick NJ, Martin PL, Cheng C, Devidas M, Pui CH, et al:
Genome-wide study of methotrexate clearance replicates SLCO1B1.
Blood. 121:898–904. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Radtke S, Zolk O, Renner B, Paulides M,
Zimmermann M, Möricke A, Stanulla M, Schrappe M and Langer T:
Germline genetic variations in methotrexate candidate genes are
associated with pharmacokinetics, toxicity, and outcome in
childhood acute lymphoblastic leukemia. Blood. 121:5145–5153. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Treviño LR, Shimasaki N, Yang W, Panetta
JC, Cheng C, Pei D, Chan D, Sparreboom A, Giacomini KM, Pui CH, et
al: Germline genetic variation in an organic anion transporter
polypeptide associated with methotrexate pharmacokinetics and
clinical effects. J Clin Oncol. 27:5972–5978. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Innocenti F, Kroetz DL, Schuetz E, Dolan
ME, Ramírez J, Relling M, Chen P, Das S, Rosner GL and Ratain MJ:
Comprehensive pharmacogenetic analysis of irinotecan neutropenia
and pharmacokinetics. J Clin Oncol. 27:2604–2614. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Teft WA, Welch S, Lenehan J, Parfitt J,
Choi YH, Winquist E and Kim RB: OATP1B1 and tumour OATP1B3 modulate
exposure, toxicity, and survival after irinotecan-based
chemotherapy. Br J Cancer. 112:857–865. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Svoboda M, Wlcek K, Taferner B, Hering S,
Stieger B, Tong D, Zeillinger R, Thalhammer T and Jäger W:
Expression of organic anion-transporting polypeptides 1B1 and 1B3
in ovarian cancer cells: Relevance for paclitaxel transport. Biomed
Pharmacother. 65:417–426. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Zhang HN, He XL, Wang C, Wang Y, Chen YJ,
Li JX, Niu CH and Gao P: Impact of SLCO1B1 521T>C variant on
leucovorin rescue and risk of relapse in childhood acute
lymphoblastic leukemia treated with high-dose methotrexate. Pediatr
Blood Cancer. 61:2203–2207. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Ramsey LB, Bruun GH, Yang W, Treviño LR,
Vattathil S, Scheet P, Cheng C, Rosner GL, Giacomini KM, Fan Y, et
al: Rare versus common variants in pharmacogenetics: SLCO1B1
variation and methotrexate disposition. Genome Res. 22:1–8. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Lima A, Bernardes M, Azevedo R, Monteiro
J, Sousa H, Medeiros R and Seabra V: SLC19A1, SLC46A1 and SLCO1B1
polymorphisms as predictors of methotrexate-related toxicity in
Portuguese rheumatoid arthritis patients. Toxicol Sci. 142:196–209.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Yuan SQ, Zhou ZW, Liang YJ, Fu LW, Chen G,
Qiu HB and Zhang LY: Correlation of chemosensitivity tested using
histoculture drug response assay to expression of multidrug
resistance genes and proteins in colorectal cancer tissues. Ai
Zheng. 28:932–938. 2009.PubMed/NCBI
|
|
13
|
Cortez MA, Scrideli CA, Yunes JA, Valera
ET, Toledo SR, Pavoni-Ferreira PC, Lee ML, Petrilli AS, Brandalise
SR and Tone LG: mRNA expression profile of multidrug resistance
genes in childhood acute lymphoblastic leukemia. Low expression
levels associated with a higher risk of toxic death. Pediatr Blood
Cancer. 53:996–1004. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Zhou S, Liao L, Chen C, Zeng W, Liu S, Su
J, Zhao S, Chen M, Kuang Y, Chen X and Li J: CD147 mediates
chemoresistance in breast cancer via ABCG2 by affecting its
cellular localization and dimerization. Cancer Lett. 337:285–292.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Wang Z, Wang N, Li W, Liu P, Chen Q, Situ
H, Zhong S, Guo L, Lin Y, Shen J and Chen J: Caveolin-1 mediates
chemoresistance in breast cancer stem cells via β-catenin/ABCG2
signaling pathway. Carcinogenesis. 35:2346–2356. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Wu H, Liu Y, Kang H, Xiao Q, Yao W, Zhao
H, Wang E and Wei M: Genetic variations in ABCG2 gene predict
breast carcinoma susceptibility and clinical outcomes after
treatment with anthracycline-based chemotherapy. Biomed Res Int
2015. 2791092015.
|
|
17
|
Won HJ, Ha TK, Kwon SJ, Cho HY, Hur SJ,
Baik HH, Suh SI, Ha E and Kim YH: Differential effects of
5-fluorouracil on glucose transport and expressions of glucose
transporter proteins in gastric cancer cells. Anticancer Drugs.
21:270–276. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Berlth F, Mönig S, Pinther B, Grimminger
P, Maus M, Schlösser H, Plum P, Warnecke-Eberz U, Harismendy O,
Drebber U, et al: Both GLUT-1 and GLUT-14 are independent
prognostic factors in gastric adenocarcinoma. Ann Surg Oncol. 22
Suppl 3:S822–S831. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Schlößer HA, Drebber U, Urbanski A, Haase
S, Baltin C, Berlth F, Neiß S, von Bergwelt-Baildon M, Fetzner UK,
Warnecke-Eberz U, et al: Glucose transporters 1, 3, 6, and 10 are
expressed in gastric cancer and glucose transporter 3 is associated
with UICC stage and survival. Gastric Cancer. 20:83–91. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Dees EC and Watkins PB: Role of cytochrome
P450 phenotyping in cancer treatment. J Clin Oncol. 23:1053–1055.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Jernström H, Bågeman E, Rose C, Jönsson PE
and Ingvar C: CYP2C8 and CYP2C9 polymorphisms in relation to tumour
characteristics and early breast cancer related events among 652
breast cancer patients. Br J Cancer. 101:1817–1823. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Boruban MC, Yasar U, Babaoglu MO, Sencan O
and Bozkurt A: Tamoxifen inhibits cytochrome P450 2C9 activity in
breast cancer patients. J Chemother. 18:421–424. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Seredina TA, Goreva OB, Talaban VO,
Grishanova AY and Lyakhovich VV: Association of cytochrome P450
genetic polymorphisms with neoadjuvant chemotherapy efficacy in
breast cancer patients. BMC Med Genet. 13(45)2012.PubMed/NCBI
|
|
24
|
Jamieson D, Lee J, Cresti N, Jackson R,
Griffin M, Sludden J, Verrill M and Boddy AV: Pharmacogenetics of
adjuvant breast cancer treatment with cyclophosphamide, epirubicin
and 5-fluorouracil. Cancer Chemother Pharmacol. 74:667–674. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Melanson SE, Stevenson K, Kim H, Antin JH,
Court MH, Ho VT, Ritz J, Soiffer RJ, Kuo FC, Longtine JA and
Jarolim P: Allelic variations in CYP2B6 and CYP2C19 and survival of
patients receiving cyclophosphamide prior to myeloablative
hematopoietic stem cell transplantation. Am J Hematol. 85:967–971.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Beelen K, Opdam M, Severson TM, Koornstra
RH, Vincent AD, Hauptmann M, van Schaik RH, Berns EM, Vermorken JB,
van Diest PJ and Linn SC: CYP2C19 2 predicts substantial tamoxifen
benefit in postmenopausal breast cancer patients randomized between
adjuvant tamoxifen and no systemic treatment. Breast Cancer Res
Treat. 139:649–655. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
van Schaik RH, Kok M, Sweep FC, van Vliet
M, van Fessem M, Meijer-van Gelder ME, Seynaeve C, Lindemans J,
Wesseling J, Van't Veer LJ, et al: The CYP2C19*2 genotype predicts
tamoxifen treatment outcome in advanced breast cancer patients.
Pharmacogenomics. 12:1137–1146. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Komatsu T, Yamazaki H, Shimada N, Nakajima
M and Yokoi T: Roles of cytochromes P450 1A2, 2A6, and 2C8 in
5-fluorouracil formation from tegafur, an anticancer prodrug, in
human liver microsomes. Drug Metab Dispos. 28:1457–1463.
2000.PubMed/NCBI
|
|
29
|
Faul F, Erdfelder E, Lang AG and Buchner
A: G*Power 3: A flexible statistical power analysis program for the
social, behavioral, and biomedical sciences. Behav Res Methods.
39:175–191. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Benjamini Y, Drai D, Elmer G, Kafkafi N
and Golani I: Controlling the false discovery rate in behavior
genetics research. Behav Brain Res. 125:279–284. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Niemi M, Pasanen MK and Neuvonen PJ:
Organic anion transporting polypeptide 1B1: A genetically
polymorphic transporter of major importance for hepatic drug
uptake. Pharmacol Rev. 63:157–181. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Custodio A, Moreno-Rubio J, Aparicio J,
Gallego-Plazas J, Yaya R, Maurel J, Higuera O, Burgos E, Ramos D,
Calatrava A, et al: Pharmacogenetic predictors of severe peripheral
neuropathy in colon cancer patients treated with oxaliplatin-based
adjuvant chemotherapy: A GEMCAD group study. Ann Oncol. 25:398–403.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Ghafouri H, Ghaderi B, Amini S, Nikkhoo B,
Abdi M and Hoseini A: Association of ABCB1 and ABCG2 single
nucleotide polymorphisms with clinical findings and response to
chemotherapy treatments in Kurdish patients with breast cancer.
Tumour Biol. 37:7901–7906. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Park SR, Kong SY, Nam BH, Choi IJ, Kim CG,
Lee JY, Cho SJ, Kim YW, Ryu KW, Lee JH, et al: CYP2A6 and ERCC1
polymorphisms correlate with efficacy of S-1 plus cisplatin in
metastatic gastric cancer patients. Br J Cancer. 104:1126–1134.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Park SR, Hong YS, Lim HS, Seong MW, Kong
SY, Kim SY, Park YI and Jung KH: Phase I clinical and
pharmacokinetic/pharmacogenetic study of a triplet regimen of
S-1/irinotecan/oxaliplatin in patients with metastatic colorectal
or gastric cancer. Cancer Chemother Pharmacol. 72:953–964. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Kim YW, Kim MJ, Ryu KW, Lim HS, Lee JH,
Kong SY, Lee JS, Choi IJ, Kim CG, Lee JY, et al: A phase II study
of perioperative S-1 combined with weekly docetaxel in patients
with locally advanced gastric carcinoma: Clinical outcomes and
clinicopathological and pharmacogenetic predictors for survival.
Gastric Cancer. 19:586–596. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Kong SY, Lim HS, Nam BH, Kook MC, Kim YW,
Ryu KW, Lee JH, Choi IJ, Lee JS, Park YI, et al: Association of
CYP2A6 polymorphisms with S-1 plus docetaxel therapy outcomes in
metastatic gastric cancer. Pharmacogenomics. 10:1147–1155. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Karadag O, Babaoglu MO, Altundag K,
Elkiran T, Yasar U and Bozkurt A: 5-Fluorouracil-induced coronary
spasm: May inhibition of hyperpolarization factors produced by
CYP2C enzymes be the cause? Oncology. 66:510–511. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Helsby NA, Lo WY, Thompson P and Laking
GR: Do 5-fluorouracil therapies alter CYP2C19 metaboliser status?
Cancer Chemother Pharmacol. 66:405–407. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Afsar A, Lee C and Riddick DS: Modulation
of the expression on constitutive rat hepatic cytochrome P450
isozymes by 5-fluorouracil. Can J Physiol Pharmacol. 74:150–156.
1996. View Article : Google Scholar : PubMed/NCBI
|
